INSTRUCTIONS FOR AUTHORS

Cancer Research is the official organ of the American Association for Cancer Research, Inc., and is devoted to the publication of significant, original research in all the subfields of cancer research, including: biochemistry and physiology; cancer chemotherapy; cell biology; endocrinology; epidemiology and biostatistics; immunology; molecular and cell biology; preclinical pharmacology and experimental therapeutics; radiobiology; and virology. Clinical investigations and epidemiological studies are published in a separate section from papers in the basic sciences.

Only those papers that report results of novel and timely studies and that meet high standards of scientific quality will be accepted. Papers are subjected to stringent review and are published within about three months of acceptance.

CATEGORIES OF PUBLICATIONS

The following types of manuscripts are accepted. (1) Papers containing results of original experimental, clinical, or statistical studies that are sufficiently well documented to be acceptable to the critical reader. (2) Concise reviews on subjects of importance to cancer researchers. Authors of unsolicited reviews should submit an outline of the proposed article for approval by the Editorial Board. If submission of the complete article is encouraged, the review will be given particularly stringent editorial evaluation before acceptance. (3) Letters to the Editor which deal with issues of importance to cancer researchers. If experimental data are included, these should be kept to the minimum required for adequate understanding. Included under this category are commentaries on manuscripts published in the Journal. If accepted, replies by the authors are invited for simultaneous publication. (4) Brief reports of meetings, symposia, and conferences related to cancer research. (5) Proceedings of symposia, published as external supplements to the Journal (Cancer Research Supplements), the full expenses of which are assumed by the sponsoring agency. These proceedings are published at the discretion of the Editor and do not undergo the usual review process. (6) Brief announcements of scientific meetings of interest to readers, of courses in cancer-related biomedical science, and of the availability of fellowships and scholarships. These should be submitted at least 3 months prior to the expected month of issue. (7) Brief announcements of recent deaths among distinguished contributors to the field of cancer research. (8) A list of books received at the Editorial Office is published periodically; the Journal does not publish book reviews.

EDITORIAL POLICY

When a manuscript is received for consideration, the Editors assume that no similar paper, other than an abstract or preliminary report, has been or will be submitted for publication elsewhere. The Editors assume that all authors listed on a manuscript have agreed to its submission. Submission of a manuscript implies acceptance of the strict policy of the journal that under no circumstances will the identities of the editors and reviewers be revealed.

Typically, the scientific review of a manuscript is handled by an Associate Editor who selects two investigators in the field as referees. The reviewers' critiques and the Associate Editor's recommended decision are then approved by the Editor. Editorial decisions, forwarded from the Editorial Office to authors, are rendered as promptly as possible, consistent with thoroughness of review; the review process usually takes an average of 8-10 weeks. If there is a marked discrepancy in the opinions of the reviewers, the Editor may send the paper to other reviewers for additional comments. In this case, more time may be needed to finalize the review process.

The Editorial Office cannot accept collect telephone calls from authors.

SUBMISSION OF MANUSCRIPTS

Contributions must be submitted in quadruplicate (the original typescript and three clear copies, with at least two sets of original illustrations) to Dr. Peter N. Magee, Editor, Cancer Research, Editorial Office, Fels Research Institute, Temple University School of Medicine, Philadelphia, Pa. 19140 (Telephone: 215-222-4720). Papers should be submitted only by an author, preferably the senior author, who should indicate in a covering letter the exact address to which all related correspondence should be sent and a telephone number at which the author can be reached. Contributors may indicate in the covering letter if they wish their papers to appear in the Clinical Investigations section; however, the final decision as to placement within the journal will be made at the discretion of the Editors. The original plus a photocopy of this letter are required.

If the manuscript contains any quoted information conveyed by either personal communication or release of unpublished experimental data, the covering letter should state specifically that authorization to use this material has been given.

A single manuscript processing fee of $60 is assessed for all manuscripts, regardless of the number of resubmissions required; this income is used to defray expenses incurred in review. Payment of this processing fee may accompany the manuscript. An invoice will be mailed with the acknowledgment of receipt of the manuscript at the Editorial Office if payment has not already been made. As a courtesy to authors editorial review will not be delayed for receipt of payment. Authors are requested to fulfill their own institutional obligations with respect to purchase orders and call numbers so that payment of the manuscript handling charge can be expedited.

Revised manuscripts should be submitted in quadruplicate, with two sets of original illustrations. A covering letter in duplicate must accompany all revised manuscripts and indicate clearly what alterations have been made in response to the reviewers' comments. Satisfactory reasons should be given for noncompliance with any of the recommendations of the Editors. Revised manuscripts may undergo another review by an Associate Editor and/or referees, particularly if the original submission required extensive changes.

If a new author has been added or an author has been deleted since the original submission, it is the responsibility of the corresponding author to ensure that the authors involved are aware of and agree to the changes in authorship. Cancer Research accepts no responsibility for such changes.

FORMAT AND STYLE

Papers should conform strictly to Journal style. A recent issue of Cancer Research will provide authors with assistance in the proper arrangement of papers. Manuscripts are to be written in clear, grammatical English. Papers that are not in good idiomatic English will be returned to the author without review. Laboratory slang as well as terminology and abbreviations not consistent with internationally accepted guidelines should be avoided.


Data must be presented concisely. Large masses of data of peripheral significance to the main thesis of the investigation will not be published in Cancer Research but may be deposited with the National Auxiliary Publications Service, c/o Microfiche Publications, P.O. Box 5313, Grand Central Station, New York, N. Y. 10017. The manuscript should contain a footnote that indicates how this ancillary material can be obtained. Such data should be submitted for review along with the manuscript.

The manuscript should be typed on 21.6- x 28-cm (8%- x 11-inch) paper with double spacing throughout, allowing for ample margins. Consecutive numbering of all pages is requested, with the title page as page 1. The typescript should be arranged in the following order: (a) title, (b) author(s) and complete name(s) and location(s) of institution(s).
Instructions for Authors

or laboratory(ies), (c) running title, (d) footnotes, (e) text, (f) tables, (g) legends for all illustrations (charts and figures), (h) illustrations, and (i) other material. Numbered and lettered sections in the text should be avoided. The appropriate location for each table and illustration should be indicated by marginal notes. Simple chemical formulas or mathematical matrixes should be presented in a form that allows their reproduction in single horizontal lines of type; more complicated mathematical formulas or chemical structures difficult to set in type should be provided in the form of India ink drawings or glossy photographs for camera-ready reproduction.

Title. Titles should be brief but informative, and limited if possible to about 100 characters. It is important for literature retrieval to include in the title the key words necessary to identify the nature of the subject matter. Use of expressions such as "Studies on..." or "Observations of..." should be avoided, since they are not sufficiently informative. Chemical formulas or abbreviations should not be used. Titles in the form of declarative sentences are not acceptable.

Authors and Their Affiliations. Authors are urged to include their full names, complete with first and middle names or initials. Confusion often arises in the literature when authors are identified by surname and initials only. Authors' academic degrees should not be included. The full names of institutions and subsidiary laboratories should be given, together with a useful address (including postal number). If several authors and institutions are listed on a paper, it should be clearly indicated with which department and institution each author is affiliated.

Running Title. A brief running title should be provided, not to exceed 50 characters.

Footnotes. Lengthy footnotes are discouraged since the same information in most footnotes can be presented more effectively in the text. Footnotes to the title page and text are to be designated consecutively with superscript Arabic numerals. A footnote to the title should contain information on financial support, including the source(s) and number(s) of the grant(s). If the paper is one of a series, a footnote to this effect may be included. Authors should also include a footnote designating to whom reprint requests should be addressed. An all-inclusive abbreviation footnote should contain a definition for every nonstandard abbreviation used in the paper.

For footnotes to tables, see section on Tables below.

Abstract. The abstract, to appear at the beginning of the paper, should be concise, yet indicative of the content of the paper. As abstracts are often copied directly by the secondary services, they should recapitulate in abbreviated form the purpose of the study and the experimental technique, results, and interpretations of the data. Data such as the number of test subjects and controls, strains of animals or viruses, drug dosages and routes of administration, tumor yields and latent periods, length of observation period, and magnitude of activity should be included. Vague, general statements such as "The results will be discussed," or "Some physical properties were studied," are uninformative and not acceptable. All important terms relevant to the content of the paper should be incorporated into the abstract to assist indexers in the derivation of key words. Abbreviations should be kept to an absolute minimum; however, if they are needed, they must be properly identified so as to make the abstract independent of the text. Authors may wish to keep in mind that "Medline," a computerized monthly bibliography prepared by the National Library of Medicine, includes only those abstracts that contain fewer than 200 words; with very few exceptions, longer abstracts are not accessible through that service.

Introduction. It is not necessary to include all of the background literature in this section. Brief reference to the most pertinent papers generally suffices to acquaint the reader with the findings of others in the field and with the problem or question to which the author's particular investigation is being addressed.

Materials and Methods. Explanation of the experimental methods should be brief but adequate for repetition by qualified investigators. Procedures that have been published previously should not be described in detail but merely cited in appropriate references. Only new and significant modifications of previously published procedures need complete exposition. The sources of special chemicals or preparations used should be given along with their locations (city and state or country if foreign).

This journal endorses the principles embodied in the Declaration of Helsinki and expects that all investigations involving humans will have been performed in accordance with these principles. For animal experimentation reported in this Journal, it is expected that the Guiding Principles in the Care and Use of Animals approved by the American Physiological Society will have been observed.

Results. This section should include a complete textual description of the results, but should not be presented in a form that allows their reproduction in single horizontal lines of type; more complicated mathematical or chemical structures difficult to set in type should be provided in the form of India ink drawings or glossy photographs for camera-ready reproduction.

Discussion. In this section, the data should be interpreted concisely without repeating material already presented in the Results section. Speculation is permitted but must be well founded.

References. Examples of the two most common types of Journal references are:


References should be typed in double-spaced form to ensure accurate copy editing. They must be arranged in alphabetical order and should include all authors' names (with initials). The bibliography should be limited to only those citations essential to the author's presentation. When comprehensive review articles are available, they are preferred to many separate references.

Before submission of the paper authors should verify the accuracy of all references and should check that all references have been cited in the text.

For articles and serial compendia. The complete title, journal, volume number, inclusive pages, and year should be given. Serial compendia, such as Advances in Cancer Research and the Annual Review of Biochemistry, which appear annually in numbered sequence, should be cited as journals rather than books, thus omitting the names of publishers and editors. Biological Abstracts should be consulted for abbreviations of journals and serials.

Books and chapter citations. Citation of a specific chapter or article in a book should carry the author(s) of the chapter, its title, editor(s) of the book, book title, edition, volume, inclusive pages of the chapter, location and name of the publisher, and year. For references to complete books, give all of the above information that is pertinent.

Papers in press and unpublished material. Papers in press may be listed among the references with the journal name and tentative year of publication. Papers in preparation or submitted for publication should be cited in a footnote, not in the References section. This rule also applies to unpublished data or personal communications. The names of all authors should be given, along with manuscript titles if possible.

Addenda. Data acquired after acceptance of the paper, by the authors themselves or others, may be included. An addendum may be added in proof upon approval by the Editor. Addenda should be kept extremely brief. The full expense of printing an addendum will be charged to the author.

Tables. Tables should be constructed so that when typeset, they will fit within a single Journal column (6.9 cm or 3½ inches). Tabular material should not duplicate data already presented in the charts. Unnecessary columns of data that can easily be derived from the rest of the results in the table should not be included. Large groups of individual values should be avoided; instead, these should be averaged and an appropriate designation of the dispersion such as standard deviation or standard error included.

Authors are obliged to indicate the significance of their observations by appropriate statistical analysis. Every table must have a descriptive title and an explanatory paragraph that clearly gives the experimental details for understanding by the reader without reference to the text. Each column must carry an appropriate heading and, if numerical measurements are given, these units should be added to the column heading. Tables should be numbered with Arabic numerals and table footnotes should be indicated with superscript italic letters (a, b, c, etc.).

All units of measurement and concentration should be clearly designated. Exponential terminology is discouraged (the term mm is preferable to 10⁻³ mm). If exponents are absolutely unavoidable in column headings, the quantity expressed should be preceded, not followed, by the power of 10 by which its value has been multiplied, i.e., 10⁻³...
x concentration (m). This will prevent confusion as to whether the quantity should be multiplied or divided to obtain the correct value.

Charts. Line-cut illustrations (graphs and drawings) are to be designated charts. Flow diagrams and complex biochemical structures should be prepared professionally (not simply typewritten) and considered charts.

Graphs should be used sparingly and only when a salient point needs illustration. Straight-line functions such as relationships between concentration and absorbance, or Lineweaver-Burk plots when these are linear, should instead be described in a few lines in the text. To conserve space those curves that may appropriately appear together should be included in a single chart.

The use of exponents for labeling coordinates in charts is considered ambiguous and should, if at all possible, be avoided. If exponents must be used, the quantity expressed should be preceded by the power of 10 by which its value has been multiplied, i.e., \(10^x\) concentration (m). The form “Concentration (m x \(10^{-3}\))” is not acceptable. If powers of 10 are used, the legend should designate how the quantity is to be calculated (whether multiplied or divided) to give the correct value.

Preparation of charts. Charts must be drawn with professional instruments and may be on Bristol board, tracing paper or cloth, or coordinate paper printed in light blue. Charts should not be mounted on heavy cardboard. Clear, glossy prints are acceptable in lieu of original drawings, provided that all parts of the chart are in focus. X-ray films or Polaroid photographs are not acceptable. If original drawings are submitted, they should not be larger than 21.6 x 28 cm (8½ x 11 inches).

Except for especially complicated drawings showing large amounts of data, all charts are published at one-column width (8.9 cm or 3½ inches) or less. It is recommended that charts be submitted in one-column size. If larger charts are submitted, it is the responsibility of the author to see that the abscissas, ordinates, lines, and especially the symbols are sufficiently large to permit reduction. When the charts are reduced to the size of a single column, the letters and numbers must be at least 1.5 mm high and the smallest part of the illustration must be discernible or the charts will be returned to the author for correction.

In original charts, this can be accomplished by having the minimum height for lower-case letters 5 mm; numerals and upper-case letters 6 mm; and symbols within the drawings 5 mm. The thickness of ruled lines on charts is also vital for clear presentation of the data. Size recommendations for lines are as follows: #1 Leroy for graph grids, bonds, and arrows; #2 Leroy for graph borders or reference lines; and #5 Leroy for graph curves or emphasis lines.

Points of observations should be denoted with different symbols rather than with different types of lines; their significance can be explained directly in the body of the chart or in the legend. Only those common symbols for which the printer has type (X, O, ●, ○, △, ■, ▲, ▼) should be used.

Charts should be ruled off close to the area occupied by the curve, and abscissas and ordinates should be clearly marked with appropriate units. Explanations of the coordinates should not extend beyond the respective lines. Do not box-in charts with top and right-hand frame lines unless these are essential for reference. If a chart contains a left- and a right-hand ordinate, explanation of the left ordinate should read in the upward direction and that of the right ordinate should read downward. Titles printed outside the confines of the charts waste space; all of this information can easily be included in the legend.

Each chart should be labeled in pencil on an adhesive label on the reverse side with Arabic numerals and the first author’s name.

Chart legends. Legends are required for all charts. They should briefly describe the data shown; details in the text need not be repeated. Each legend should adequately identify all units, abbreviations, mathematical expressions, abscissas, ordinates, and symbols.

Figures. Because halftone illustrations (photomicrographs and photographs) are expensive to reproduce, only those photographs that are absolutely essential to the clarity of the presentation can be accepted. It is often difficult for the printer to judge accurately the amount of reduction necessary to fit the electrophoretic patterns. Therefore, this material should be submitted in reduced form ready for photoreproduction.

Color photographs are discouraged and will be published only if the Editors deem them indispensable. The complete expense of reproducing such photographs will be charged to the author. The author is also responsible for submitting prints that are of sufficient quality to permit accurate reproduction, and for approving the final color proof. Cancer Research assumes no responsibility for the quality of the photograph as it appears in the journal. Current estimates for color reproduction can be obtained from the Editorial Office.

Preparation of plates. Photographs should be mounted on “plates” of white cardbord; the overall dimensions of photographs on a given plate should not exceed 18.4 x 22.4 cm (7¼ x 9 inches). All photographs should be correctly exposed, sharply focused, and submitted on glossy white paper.

Karyotypes should be presented in the form of cardboard plates onto which chromosome sections from an original photomicrograph are pasted. This “original” is needed for clear Journal reproduction. The back of the plate should indicate how much it can be reduced in size if published. For review purposes, two additional glossy photographs are requested.

Considerable space may be saved by cropping figures so that 4 to 6 photographs can be presented on one plate. Plates with only single photographs are not acceptable and will be returned for cropping or reduction unless the authors can justify their necessity. Photographs should be butted together; tooling (thin white lines) between the photographs will be added by the printer.

Figure numbers, in Arabic numerals, should appear in India ink directly on the photographs and, if possible, should be in the lower right-hand corner of each photograph. These numbers should be no larger than ¼ inch. Wax-based lettering such as PRES-TYPE or LE-TAPSET is discouraged because of its tendency to crumble and adhere to vinyl overlays. Photomicrographs should have internal scale markers. Symbols, arrows, or letters used in photomicrographs should contrast with the background.

Tissue overlays on plates are a necessary protection for figures. Indicate on overlays the important areas of the photographs that must be reproduced with greatest fidelity. The top of the figure and the first author’s name should be given in pencil on an adhesive label on the reverse side of each plate.

Figure legends. An appropriate legend for each figure, including stains and magnifications where applicable, is required. Any abbreviations or reference points on a figure should be explained in the legend. All attempts will be made to place legends under the plates to which they refer. To facilitate proper layout, authors should keep their plates to 7¼ x 8½ inches.

ABBREVIATIONS

Abbreviations are in general a hindrance to readers in fields other than that of the author(s), to abstractors, and to scientists in foreign countries. Authors should limit their use to an absolute minimum. Single words should not be abbreviated, e.g., daunomycin, folate, vincristine. Abbreviations are not to be used in titles, but running titles may carry abbreviations for purposes of brevity. Abstracts may contain abbreviations for terms mentioned many times in that section but their identification is mandatory.

Authors should follow the recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature (see section below on Terminology). All nonstandard abbreviations should be identified in an inclusive abbreviation footnote to the first such abbreviation after the Abstract.

Abbreviations that form recognizable words, such as EAT and MOPS, are discouraged.

Standard Abbreviations. Authors may use, without definition, the abbreviations in the following lists.

- NAD®, NADH: nicotinamide adenine dinucleotide and its reduced form
- NADP®, NADPH: nicotinamide adenine dinucleotide phosphate and its reduced form (DPN®, TPN®, and their reduced forms are not acceptable.)
- CoA, acyl-CoA: coenzyme A and its acyl derivatives (e.g., acetyl)
- AMP, GMP, IMP, UMP: the 5'-phosphates of ribosyladenine,

Instructions for Authors
in a substance is labeled by means of the same isotope and the positions are not indicated, the number of labeled atoms is added as a subscript to the right of the element, as in [1-14C]glucolic acid. The symbol U indicates uniform labeling and G, general labeling, e.g., [U-
14C]glucose (where the 14C is uniformly distributed among all six positions) and [G-14C]glucose (where the 14C is distributed among all six positions, but not necessarily uniformly).

The isotopic prefix precedes that part of the name to which it refers, as in sodium [2,3-3H]biotin, [3,5-3H]acetic acid, 1-amino[14C]methyl-cyclopentanol, [2H]tetrazole, [U-14C]fructose, 5-([1-32P])diphosphate, 17H([14]estradiol. Terms such as "labeled albumin" should not be contracted to "labeled" albumin" (since native albumin does not contain iodine), and "14C-labeled amino acids" should similarly not be written as "14C-amino acids" (since there is no carbon in the amino group).

When isotopes of more than one element are introduced, their symbols should be arranged in alphabetical order, e.g., [3-14C; 2,3-D; 15N]serine. Deuterium and tritium may be designated as 2H and 3H or as D and T, respectively.

When not sufficiently distinguished by the foregoing means, the positions of isotopic labeling are indicated by Arabic numerals, Greek letters, or prefixes in italics, as appropriate; these are to be placed within square brackets to appear before the symbol of the element concerned and are attached to it by a hyphen. Examples of this style are: [1-14C]thymidine, L-[2-14C]leucine or L-[2-14C]leucine, [carboxyl-14C]leucine, [2,3-14C]maleic anhydride, [3,4-14C; 35S]methionine, L-[2-methyl-14C]methionine. The symbol indicating configuration always precedes the bracketed isotope, and a hyphen is used to separate it from the bracket, e.g., O-[14C]glucose; L-[1-14C]leucine.

The same rules apply when the labeled compound is designated by a standard abbreviation or symbol other than the atomic symbol, e.g., [α-32P]ATP, [32P]CMP, or [14]IUrD. The square brackets are not to be used, however, with atomic symbols, or when the isotopic symbol is attached to a word that is not a specific chemical name, abbreviation, or symbol. Proper usage here is: [14CO2], [1H2O], [H35SO4], [32P], [131I]labeled, [14H]-ligands, [14C]-steroids.

Enzymes. Authors should use the Recommended Name given by the Nomenclature Committee of the International Union of Biochemistry on the Nomenclature and Classification of Enzymes (Academic Press, Inc., New York, 1979). In some cases the Systematic Name or the reaction catalyzed should also be included. It is strongly recommended that the Enzyme Commission number be stated at first mention.


Histones. Histone nomenclature should conform to the following system proposed at a Ciba conference held on April 4–5, 1974, in London: the six histone fractions are to be labeled H1, H1*, H2A, H2B, H3, and H4, rather than F1, F1*, F2a2, F2b, F3, and F2a1, respectively.

Interferon Assays. When reporting the calibration of interferon assays, authors should state the name, identifying number, and assigned potency of the international standard used to calibrate their assay, along with the observed geometric mean titer of the standard, the standard deviation of that value, the number of titrations performed to obtain that value, and the technical details of the assay.


Drugs. Generic names of drugs are preferred; a proprietary name may be used only after the first mention of the generic name and should be avoided in titles unless both names can easily be listed. If a foreign proprietary name is used, the name of the comparable U. S. product should be given. When there is no generic name for a drug, authors should give the chemical name or formula or a description of the active ingredients.

Authors should refer to the formally adopted generic names listed in USAN and the USP Dictionary of Drug Names (1980). In addition, the Council on Drugs reports in The Journal (New Names) drug names adopted by the USAN (United States Adopted Names) Council. These monographs include both the generic and proprietary names for the newest drugs, usually prior to their publication elsewhere.

Tumors. Tumors used in experimental investigations should be clearly described and identified in acceptable terminology. If these tumors are well known and have been identified in previous publications, extended descriptions and photomicrographs are unnecessary.

General. The composition of all solutions and buffers should be specified in sufficient detail so that the concentration of each component can be determined. The word "saline" should be replaced by "NaCl solution," along with the exact concentration. Inexact terms such as "physiological saline" or "phosphate-buffered saline" are not permitted; exact contents and concentrations should be given.

Decimals are preferred to fractions: the form 0.01, not .01, is required in text, tables, and charts.

Ionic charge should be designated by a superscript immediately following the chemical symbol, e.g., Mg++, S-.

Advice on biochemical nomenclature is readily available from Dr. Waido E. Cohn, Director, Office of Biochemical Nomenclature, Biology Division, Oak Ridge National Laboratory, Box Y, Oak Ridge, Tennessee 37830.

ALTERATIONS IN PROOF

The Journal provides authors with galley proofs for their examination. Extensive alterations in proof lead to sharply increased costs and delays in publication and will necessarily be charged to the authors. We urge our contributors to proofread and edit their manuscripts carefully before submission. The Editors retain the prerogative to question minor stylistic alterations and major alterations that might affect the scientific content of the paper. The authors may or may not be contacted, depending on the nature of corrections in proof. If proof is not returned to the Editorial Office within 48 hours of receipt, it may be necessary to reschedule the paper for a subsequent issue.

REPRINTS

Reprint order forms are sent to authors along with their proof. If the form has been omitted inadvertently from the shipment, the Editorial Office should be contacted immediately.

Orders are to be placed prior to publication according to the schedule of prices given on the form. Reprint order forms must be returned to the Editorial Office along with the corrected proof; purchase orders should be issued and sent directly to Waverly Press, Inc., Mount Royal & Guilford Avenues, Baltimore, Maryland 21202. Requests for additional reprints should be addressed to Waverly Press, Inc. A 25% handling charge will be added to the price of reprints ordered after the Journal has been released for press.

Reprints are normally shipped 6 weeks after publication of the Journal.

It is helpful to the reader if a footnote is included in the paper indicating to which author reprint requests should be addressed.

COPYRIGHT

Under the copyright law (PL 94-553) which became effective January 1, 1978, copyright for written material is vested in the author from

JANUARY 1983

449
Instructions for Authors

the moment of its creation and remains the property of the author until legally transferred. For this reason it has become necessary to require that all authors who wish to publish in Cancer Research formally transfer copyright to the proprietor of the Journal, namely, Cancer Research, Inc., the publishing subsidiary of the American Association for Cancer Research. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, and display. However, the Journal will continue its policy of allowing authors (or others with the permission of the authors) to include the copyrighted material in reviews, books, or subsequent papers, upon written request to the Editor. It is understood in conveying copyright that the authors have not published this material elsewhere, either whole or in part (except in abbreviated form as a preliminary communication), and that they have neither concluded previous negotiations nor initiated pending negotiations for copyright of this material.

When a manuscript has been written by two or more authors, one of them will be designated senior author and will negotiate copyright transfer in the name of all of the authors.

The federal government has determined that it has a nonexclusive right to publish or republish material developed from work performed under federal grant-supported projects. Therefore, copyrights for such works are subject to this restriction. Since the federal government does not recognize private copyright for work performed by its employees as part of their official duties, the Journal will accept papers from government laboratories without copyright transfer, provided that the authors abide by the same provisions required of other authors.

Appropriate forms for transfer of copyright will be sent routinely with acknowledgment of receipt of manuscripts. They may also be requested from the Cancer Research Editorial Office. The Journal will not accept a paper unless the form is properly filled out and signed.

The appearance of the code 0008-5472/83/0043-0000$02.00 at the top of the first page of an article in Cancer Research indicates that the copyright owner has consented that copies of the article may be made for personal or internal use, provided that the copier pay the stated per-copy fee of $2.00 through the Copyright Clearance Center, Inc. This Center is a nonprofit organization through which individuals and institutions may reimburse a copyright owner for photocopying of journal articles beyond what is defined as "fair use" in Sections 107 and 108 of the Copyright Revision Act of 1978.

Those who wish to photocopy Cancer Research articles may report the number they have made together with the fee code to: Copyright Clearance Center, Inc. Operations Office, P. O. Box 765, Schenectady, New York 12301. Remittances may be sent to the Center at the time of reporting or the Center will bill the user on a monthly basis. Deposit accounts and prepayment plans may also be arranged.

Articles from any issue of Cancer Research dating from 1973 may be photocopied under the same conditions and at the same fee. If there is no fee code, as in issues prior to June 1978, the user should report the title of the Journal, the month of the issue, and the initial page number of the article, together with a statement of the number of copies made. If an article published after June 1978 does not carry a fee code, it is understood to be in the public domain and may be copied without restriction or payment of a fee.

REPRODUCTION PERMISSION

Reproduction permission will usually be granted by Cancer Research, Inc., owner of the copyright, for legitimate purposes. Requests for reproduction of published material, along with a brief description of intended use, should be made by writing to the Editor. Third parties should obtain the approval of the authors before corresponding with the Editor.

ADVERTISEMENTS

Advertisement insertion orders and copy must be received 60 days prior to the month of issue in which the advertisement is to be published. The Journal is mailed on or about the 20th of the month preceding the month of issue. Inquiries regarding advertising should be directed to: Donald H. Nichols, Vice President, Journal Sales, Waverly Press, Inc., 428 East Preston St., Baltimore, Maryland 21202. Telephone: 301-528-4280.

SUBSCRIPTIONS AND BUSINESS INQUIRIES

All subscriptions and business matters are handled by the publisher, Waverly Press, Inc., 428 East Preston Street, Baltimore, Maryland 21202. Telephone: 301-528-4000. Subscriptions are payable in advance to the publisher. The regular annual subscription price of Cancer Research for members of the American Association for Cancer Research, Inc. is $40. Individuals who are not members of the Association may subscribe to the Journal at the rate of $80 for domestic subscribers per annual volume. The domestic institutional subscription rate is $140.00 per annual volume. Corresponding members, nonmembers and institutions outside the United States and Canada should add $30.00 to these rates to cover the cost of postage.

The publisher should be notified of changes of address 60 days in advance; subscribers should give both their old and new addresses. Members of the American Association for Cancer Research should also inform the Executive Director, Margaret Foti, Temple University School of Medicine, West Building, Room 301, Philadelphia, Pa. 19140 of their changes of address.

No responsibility is accepted by the Editors, by Cancer Research, Inc., by the American Association for Cancer Research, Inc., or by the publishers of Cancer Research for opinions expressed by the contributors or for the content of advertisements.
AUTHOR INDEX

January 1983

Aaronson, S. A., 1
Ahluwalia, M. B., 28
Alhonen-Hongisto, L., 324
Antoniades, H. N., 83
Ashurst, S. W., 163
Åström, A., 342
Aukerman, S. L., 175

Baggolimi, M., 22
Bara, J., 355
Barrett, A., 287
Barrett-Boone, L. A., 245
Bast, R. C., Jr., 197
Bauer, E., 125
Bems, M. W., 430
Berry, R. J., 374
Biedler, J. L., 222
Bignone, F. A., 202
Blumberg, P. M., 11
Blumenschein, G. R., 210
Bode, U., 229
Bohn, W. H., 403
Braatz, J. A., 110
Brambilla, G., 202
Breeding, J. H., 171
Brock, N., 333
Brundrett, R. B., 175
Burns, R. G., 430
Burtin, P., 355

Cajelli, E., 202
Cameron, I. L., 73
Cameron, R., 313
Carlo, P., 202
Carlson, S., 114
Carter, W. H., Jr., 60
Cass, M., 287
Cayama, E., 188
Cefalu, W., 125
Chalet, M., 171
Chambaz, E. M., 386
Chamness, G. C., 413
Chan, C., 28
Chang, R. L., 192
Chello, P. L., 97, 104
Cho-Chung, Y. S., 295
Clark, G. M., 413
Cochet, C., 386
Cockley, K. D., 403
Coffey, R. G., 150
Cohen, S. M., 182
Colbert, D. A., 229
Conney, A. H., 192
Connor, M. J., 171
Crane, M. M., 422
Craven, P. A., 35
Curtis, S., 349
Custer, R. P., 279

Daher, N., 355
Dahlman, A., 430
Darbre, P., 349
Decaens, C., 355
Deisseroth, A. B., 229
DePierre, J. W., 342
DeRubertis, F. R., 35
Deutsch, V., 303
Dewald, B., 22
Diamond, L., 163
DiGiovanni, J., 163
Dill, P. L., 258
Dillman, R. O., 417
DiPaolo, J. A., 273
Dorick, D. M., 97, 104
Drewinko, B., 210
Earle, M. F., 133
Eker, P., 320
Enomoto, K., 188
Erro, V., 392
Evans, C. H., 273
Farber, E., 28, 188, 313
Fidler, J. I., 400
Finesilver, A., 374
Finollo, R., 202
Fontana, J. A., 229
Fox, J. W., 35
Frost, P., 125
Giannini, E. H., 422
Giovanella, B. C., 422
Glass, J. P., 435
Glazer, R. I., 133
Gold, D. V., 235
Gorelik, E., 138
Graves, D. T., 83
Grdina, D. J., 146
Greiner, J. W., 273
Guenther, T. M., 313
Hadden, J. W., 150
Hagenbeek, A., 408
Halter, S. A., 245
Hart, I. R., 400
Hartman, P. E., 175
Harvey, A. E., 374
Hayata, I., 367
Hehmann, R., 392
Hersh, E. M., 422
Hicks, R. M., 374
Hillman, E. A., 245
Hilton, J., 175
Hirashima, K., 367
Holder, W. D., Jr., 239
Hollingsworth, P., 235
Hoon, D. B. S., 114
Hopkins, H. A., 60
Horaguchi, K., 439
Hovis, J., 46
Hua, D. T., 110
Hug, V., 210
Hull, D. F., III, 413
Hultborn, R., 363
Hunter, G., 287
Ishihara, T., 367
Jaken, S., 11
Jänecke, J., 324
Jerina, D. M., 192
Jetten, A. M., 68
Johnson, F. M., 430
Kallio, A., 324
Kapoor, C. L., 295
Kennedy, K. A., 54
Kerbel, R. S., 125
King, R. J. B., 349
Kline, S. A., 159
Knight, W. A., III, 413
Knowles, M. A., 374
Koziol, J. A., 417
Kremer, T., 235
Kurnick, N. B., 258
Lästbom, T., 333
Laug, W. E., 22
Ledda, A., 202
Lee, G., 28, 188
Leib-Mösch, C., 392
Levin, W., 192
Ley, R. D., 41
Lijsnky, W., 214
Lippman, M. E., 258
Longerbeam, M. B., 60
Looney, W. B., 60
Loran, R., 303
Lowe, N. J., 171
Marsili, M. A., 15
Martens, A. C. M., 408
Mason, G. R., 430
McGuire, W. L., 413
Mehta, B. M., 435
Meijer, J., 342
Melchionne, S., 159
Meyers, M. B., 222
Mian, T. A., 146
Millas, L., 6
Montgomery, J. A., 97, 104
Morgan, A. C., 422
Murasaki, G., 182
Nagai, A., 46
Nelson, D., 235
Neumann, G., 303
Nicolson, G. L., 6
Nitta, K., 328
Novak, R., 287
Nowicki, D., 287
Obrist, R., 197
Oesch, F., 313
Oikawa, A., 439
Ormsad, K., 333
Orrenius, S., 333
Osbourne, C. K., 413
Owen, A. J., 83
Peterson, R. H. F., 222
Pohl, J., 333
Pool, T. B., 73
Princic, G. L., 110
Ramshaw, I., 114
Reuber, M. D., 214
Roberts, E., 20
Robinson, M. K., 15
Rosa, B., 355
Ross, W. E., 120
Rossen, R. D., 422
Sado, T., 367
Sakai, S., 439
Sanner, T., 320
Sarma, D. S. R., 28
Sartorelli, A. C., 54
Schaeter, F. V., 279
Scheinberg, D. A., 265
Schaters, H., 392
Schnyder, J., 22
Scott, R. E., 88
Seidman, I., 159
Seki, M., 367
Seppänen, P., 324
Shapiro, W. R., 435
Sherwin, S. A., 403
Shupnik, M. A., 11
Siegfried, J. M., 54
Sina, J. F., 163
Singer, J. M., 163
Sirotnak, F. M., 97, 104
Smith, N. K. R., 73
Solt, D. B., 188
Sorof, S., 279
Sparks, R. L., 73
Spengler, B. A., 222
Spitzer, G., 210
Stehlin, J. S., 422
Stekar, J., 333
Strand, M., 265
Tada, M., 192
Takeuchi, M., 328
Talmadge, J. E., 400

JANUARY 1983

451
Tartar, N., 197
Tartamella-Biondo, R., 125
Tashjian, A. H., Jr., 11
Terata, N., 46
Theiss, J. C., 146
Todaro, G. J., 403
Tohda, H., 439
Tomasovic, S. P., 6
Tritton, T. R., 54
Truitt, G. A., 15
Trump, B. F., 245
Tsuda, H., 188
Tviet, E., 363
Twardzik, D. R., 403
Twomey, J. J., 422
Uehara, N., 333
Valerio, M. G., 245
Valone, F. H., 197
Van Duuren, B. L., 159
Varghese, A. J., 78
Vilgrain, I., 386
Vogel-Bindel, U., 313
Vyas, K. P., 192
Wang, G-H., 339
Wang, M-Y., 339
Warrington, R., 114
Weisenthal, L. M., 258
Weiss, L., 363
Welch, D. R., 6
Wells, S. A., Jr., 239
Wheelock, E. F., 15
Whitmore, G. F., 78
Wile, A. G., 430
Wood, A. W., 192
Wozniak, A. J., 120
Xu, M-S., 339
Yagi, H., 192
Yamagiwa, J., 367
Yang, C-H., 97
Yap, T-G., 287
Yates, J., 349
Yoshida, K., 367
Yu, F-L., 287
Yun, K., 88
Zbar, B., 46
Zhang, W-X., 339
Ziola, B., 114
This publication is available in microform.

University Microfilms International

Please send additional information for (name of publication)

Name ____________________________________________
Institution ________________________________________
Street ____________________________________________
City ______________________________________________
State __________ Zip __________

300 North Zeeb Road
Dept. P.R.
Ann Arbor, Mi. 48106
U.S.A.

30-32 Mortimer Street
Dept. P.R.
London W1N 7RA
England
There is a road.

Many cancer patients need transportation to and from treatments. That's why the American Cancer Society has formed groups of volunteers across the United States who give a few hours of their time each month to drive them. The road to recovery can be a long and difficult one, but it can be much easier when there are friends who can help along the way.

American Cancer Society